About Centurion BioPharma Corporation
Centurion BioPharma Corporation
Fighting cancer with cutting-edge science
Private company with focus on preclinical research in oncology
Discovered and owns full rights to LADR™ platform
Laboratory facility and discovery team located in Freiburg, Germany
Subsidiary of CytRx Corporation (CYTR) with an administrative office in Los Angeles, CA
Engesserstraße 4, 79108 Freiburg im Breisgau, Germany
CEO and President
Mr. Curtis brings 25 years of life science leadership experience, with oncology and orphan diseases his specialty. He was instrumental in the US and global development and commercialization of many successful drugs, including Votrient®, Doxil®, Velcade®, Benlysta®, Tykerb® and Adempas®. Prior to joining Centurion, Mr. Curtis served as President and Chief Operating Officer of CytRx Corporation. Before that, he served as President, U.S. Commercial at Aegerion Pharmaceuticals (now Novelion Therapeutics), Vice President and General Manager – Rare Disease/Cardiopulmonary Business Unit at Bayer Healthcare, and in positions of increasing responsibility at GlaxoSmithKline, culminating in his role as Vice President, Marketing and Global Commercial Leader. Mr. Curtis earned a Master of Business Administration degree from Pennsylvania State University, and holds a Bachelor of Science degree from the University of Pittsburgh, where he double-majored in Business and Psychology.
Chief Financial Officer
Mr. Caloz has an accomplished history of providing senior financial leadership in the life sciences sector, including as Chief Financial Officer of Occulogix, Inc, a NASDAQ listed, a medical therapy company. Prior to that, Mr. Caloz served as Chief Financial Officer of IRIS International Inc., a Chatsworth, CA based medical device manufacturer. He served as Chief Financial Officer of San Francisco-based Synarc, Inc., a medical imaging company, and from 1993 to 1999 he was Senior Vice President, Finance and Chief Financial Officer of Phoenix International Life Sciences Inc. of Montreal, Canada, which was acquired by MDS Inc. in 1999. Mr. Caloz was a partner at Rooney, Greig, Whitrod, Filion & Associates of Saint Laurent, Quebec, Canada, a firm of Chartered Accountants specializing in research and development and high tech companies, from 1983 to 1993. Mr. Caloz, a Chartered Accountant, holds a degree in Accounting from York University, Toronto, Canada. Mr. Caloz also serves as CFO of CytRx Corporation.
Felix Kratz, Ph.D.
Vice President Drug Discovery
Dr. Kratz is a medicinal chemist with more than 25 years of pertinent experience in the preclinical development of anticancer drugs, prodrugs and protein conjugation chemistry and profound knowledge of translational research from the laboratory to the clinic. He has successfully transferred aldoxorubicin, CytRx clinical lead compound, from bench to bedside that is based on an innovative drug delivery platform exploiting circulating albumin as a tumor-specific drug carrier. Felix Kratz graduated in Chemistry from the University of Heidelberg with Magna Cum Laude. Prior to joining Centurion, Dr. Kratz served as Vice President Drug Discovery at CytRx Corporation. He established the Division of Macromolecular Prodrugs at the Tumor Biology Center Freiburg. He serves on the Editorial Board for Bioconjugate Chemistry, Current Medicinal Chemistry, Current Bioactive Compounds, and Pharmacology & Pharmacy and has authored approximately 260 scientific publications, book articles and proceedings and is the inventor of over 20 patents and patent applications. As Vice President he heads Centurion Drug Discovery located in Freiburg, Germany.
Anna Warnecke, Ph.D.
Senior Director Drug Discovery
Dr. Warnecke is a medicinal chemist with more than 15 years of relevant experience in the preclinical development of oncology prodrugs. Prior to joining Centurion, from 2009 through 2014, Dr. Warnecke served as the Head of Chemistry in the Division of Macromolecular Prodrugs, Tumor Biology Center, where she worked very closely with Dr. Kratz, having advanced from her initial position as a research associate starting in 2002. Dr. Warnecke completed her Ph.D. at the Department of Macromolecular Chemistry, University of Freiburg, with a thesis entitled “Maleimide-functionalized Water-Soluble Derivatives of Clinically Established Anticancer Drugs.” She is the inventor or co-inventor on more than 15 patents and patent applications, both prior to and since joining Centurion, as well as authoring numerous articles published in scientific journals. In addition to her research work, as Senior Director Dr. Warnecke is responsible for occupational health and safety compliance of the laboratory facilities, and handling human resources matters, which includes recruiting and supervising qualified staff.